Metabolism of antisense oligonucleotides in rat liver homogenates

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 140-149

  Crooke, Rosanne M ^a   Graham, Mark J ^a   Martin, Michael J ^a   Lemonidis, Kristina M ^a   Wyrzykiewiecz, Tad ^a   Cummins, Lendell L ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GENE PRODUCT; NUCLEASE; PHOSPHOROTHIOIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ION CONDUCTANCE; LIVER HOMOGENATE; LIVER METABOLISM; LIVER PARENCHYMA; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RAT;

ANIMALS; DRUG STABILITY; ENDONUCLEASES; EXONUCLEASES; HYDROGEN-ION CONCENTRATION; LIVER; MALE; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; OSMOLAR CONCENTRATION; OXIDATION-REDUCTION; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 0033981544     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Alul RH, Singman CN, Zhang G and Letsinger RL (1991) Oxalyl-CPG: A labile support for synthesis of sensitive oligonucleotide derivatives. Nucleic Acids Res 19:1527-1532.
2. Bennett CF (1993) Antisense oligonucleotides in inflammation research and therapeutics, in Antisense Research and Applications (Crooke ST and LeBleu B eds) pp 547-562, CRC Press, Boca Raton, FL.
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Butler M, Stecker K and Bennett CF (1997) Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77:379-388.
5. Cohen AS, Bourque AJ, Wang BH, Smisek DL and Belenky A (1997) A nonradioisotope approach to study the in vivo metabolism of phoaphorothioate oligonucleotides. Antisense Nucleic Acid Drug Dev 7:13-22.
6. Cook PD (1998) Antisense medicinal chemistry, in Antisense Research and Application: Handbook of Experimental Pharmacology (Crooke ST ed) vol 131, pp 51-101, Springer-Verlag, Berlin.
7. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267:1181-1190.
8. Crooke RM (1998) In vitro cellular uptake, distribution, and metabolism of oligonucleotides, in Antisense Research and Application: Handbook of Experimental Pharmacology (Crooke ST ed) vol 131, pp 103-140, Springer-Verlag, Berlin.
9. Crooke RM, Graham MJ, Cooke ME and Crooke ST (1995) In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 275:462-473.
10. Crooke ST (1996) Commentary: Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev 6:145.
11. Crooke ST (1997) Preface. Anticancer Drug Design 12:311-313.
12. Crooke ST (1998) Basic principles of antisense therapeutics, in Antisense Research and Application: Handbook of Experimental Pharmacology (Crooke ST ed) vol 131, pp 1-50, Springer-Verlag, Berlin.
13. Crooke ST and Bennett CF (1996) Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 36:107-129.
14. Cummins LL, Winniman M and Gaus HJ (1997) Phosphorothioate oligonucleotide metabolism: Characterization of the "N+"-mer by CE and HPLC-ES/MS. Bioorg Med Chem Lett 7:1225-1230.
15. Eckstein F (1985) Nucleoside phosphorothioates. Annu Rev Biochem 54:367-402.
16. Gao W-Y, Han F-S, Storm C, Egan W and Cheng Y-C (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol Pharmacol 43:223-229.
17. Garvey JS and Caperna TJ (1981) Collection and enrichment of Kupffer cells, in Manual of Macrophage Methodology (Herscowitz HB, Holden HB, Bellanti JA and Ghaffer A eds) pp 31-35, Marcel Dekker, New York.
18. Geary RS, Leeds JM, Fitchett J, Burckin T, Truong L, Spainhour C, Creek M and Levin AA (1997a) Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos 25:1272-1282.
19. Geary RS, Leeds JM, Henry SP, Monteith DK and Levin AA (1997b) Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Design 12:383-393.
20. Gilar M, Belenky A, Smisek DL, Bourque A and Cohen AS (1997) Kinetics of phosphorothioate oligonucleotide metabolism in biological fluids. Nucleic Acids Res 18:3615-3620.
21. Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis KM, Stecker KK, Martin MJ and Crooke RM (1998) In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 286:447-458.
22. Green CE, Dabbs JE and Tyson CA (1983) Functional integrity of isolated rat hepatocytes prepared by whole liver vs biopsy perfusion. Anal Biochem 129:269-276.
23. Kouidou SA, Triantos AA, Papageorgiou GE, Kavoukopoulos EM, Vavatsi NA and Trakatellis AC (1987) Single-strand-specific nuclease from rat liver endoplasmic reticulum: Characterization and mode of action. Int J Biochem 19:857-864.
24. Koziolkiewicz M and Stec WJ (1992) Application of phosphate-backbone-modified oligonucleotides in the studies on EcoRI endonuclease mechanism of action. Biochemistry 31:9460-9466.
25. Koziolkiewicz M, Wojcik M, Kobylanska A, Karwowski B, Rebowska B, Guga P and Stec WJ (1997) Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: Diastereoselectivity of plasma 3′-exonuclease. Antisense Nucleic Acid Drug Dev 7:43-48.
26. Krotz AH, Cole DL and Ravikumar VT (1996) Synthesis and deprotection of B-silylethyl protected O, O, O,-and O, O, S-trialkylphosphorothioates. Tetrahedron Lett 37:1999-2002.
27. Leeds JM and Geary, RS (1998) Pharmacokinetic properties of phosphorothioate oligonucleotides in humans, in Antisense Research and Application: Handbook of Experimental Pharmacology (Crooke ST ed) vol 131, pp 217-232, Springer-Verlag, Berlin.
28. Leeds JM, Geary RS, Henry SP, Glover J, Shanahan W, Fitchett J, Burckin T, Truong L and Levin AA (1997) Pharmacokinetic properties of phosphorothioate oligonucleotides. Nucleosides Nucleotides 16:1689-1693.
29. Malicka-Blaszkiewica M (1990) Rat liver DNase-I-like activity and its interaction with actin. Z Naturforsch [C] 45:1165-1170.
30. Nicklin PL, Craig SJ and Phillips JA (1998) Pharmacokinetic properties of phosphorothioates in animals-absorption, distribution, metabolism and elimination, in Antisense Research and Application: Handbook of Experimental Pharmacology (Crooke ST ed) vol 131, pp 141-168, Springer-Verlag, Berlin.
31. Plenat F, Klein-Monohoven N, Marie B, Vignaud JM and Duprez A (1995) Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice: An autoradiographic, immunohistological, and direct fluorescence microscopy study. Am J Pathol 147:124-135.
32. Potter BVL, Romaniuk PJ and Eckstein F (1983) Stereochemical course of DNA hydrolysis by nuclease S. J Biol Chem 258:1758-1760.
33. Potter JL, Laurila U-R and Laskowski M (1958) Studies of the specificity of Deoxyribonuclease I. 1. Hydrolysis of a trinucleotide. J Biol Chem 233:915-916.
34. Ralph RK, Smith RA and Khorana HG (1962) Studies on polynucleotides. XV. Enzymic degradation. The mode of action of pancreatic deoxyribonuclease on thymidine, deoxycytidine, and deoxyadenosine polynucleotides. Biochemistry 1:131-137.
35. Rifai A, Brysch W, Fadden K, Clark J and Schlingensiepen K-H (1996) Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am J Pathol 149:717-725.
36. Spitzer S and Eckstein F (1988) Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides. Nucleic Acids Res 16:11691-11704.
37. Vavatsi NA, Kouidou SA, Triantos AA, Kavoukopoulos EM, Papageorgiou GE and Trakatellis AC (1991) Cellular and tissue distribution of a single-strand-specific nuclease. Int J Biochem 23:27-31.